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fifteen-year-old adolescents, utilizing pharmacy students
as instructors.
METHODS: A cost-effectiveness study is conducted to
determine the cost per student who passed the knowledge
based exam on tobacco use, after attending the lecture
sessions of the tobacco outreach program. The primary
outcome of interest is the number of adolescents able to
pass the post-test, compared to the number able to pass
the pre-test. The following direct costs were collected:
supplies; materials; travel; consultant fees; primary inves-
tigator salary; coordinator salary; student teacher salary
and training; cost of classroom/space, and value of do-
nated goods. Only the incremental costs and outcomes
are utilized to calculate the CE ratio. No indirect costs or
discounting is included in the analysis.
RESULTS: A total of 132 students participated in the
program during a period of one year. The average cost
per student is $389.00. Pre-test and post-test are adminis-
tered to seventy-eight of these students. The cost-effec-
tiveness ratio per student who received a higher grade on
the post-test versus the pre-test is $689.59. The cost-effec-
tiveness ratio per student who received a grade greater
than seventy on the post-test compared to the pre-test is
$2,167.28.
CONCLUSIONS: This study evaluates the impact on the
post-test scores compared to the pre-test scores only. It
does not evaluate the impact of this program either on
behavioral changes associated with tobacco use, or on
the indirect benefit of being exposed to positive role mod-
els, the students from the college of pharmacy. The aver-
age per-student program cost of this study population is
consistent with published literature. However, very little
literature exists to determine if the CE ratios are within
the standards of other drug abuse educational programs.
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OBJECTIVE: To perform a retrospective economic anal-
ysis of The Coronary Angioplasty Amlodipine Restenosis
Study (CAPARES), in order to evaluate the pharmaco-
economic profile associated with the use of amlodipine in
patients undergoing angioplasty from the perspective of
the UK National Health Service
METHODS: A decision analysis was undertaken to track
the experiences of patients admitted for angioplasty who
were prescribed amlodipine versus those administered
placebo. The analysis modeled a four-month time period,
which included an initial hospitalization for angioplasty,
outpatient follow-up care and any re-admissions for car-
diovascular events. The CAPARES trial provided the out-
come data for the amlodipine and placebo patients. Out-
comes tracked in the analysis included MI, repeat PTCA,
CABG, and all-cause mortality. Economic data for inpa-
tient stays, procedures, physician services, laboratory
tests and pharmaceuticals were obtained from published
data, and a physician panel was used to estimate the
quantity of outpatient resource consumption.
RESULTS: The total expected cost per patient using and
not using amlodipine was £3,833 and £4,035, respec-
tively, resulting in a net cost savings of £202 over the
four-month time period. The cost savings is primarily due
to savings in inpatient costs due to the reduction in ad-
verse events requiring repeat revascularization and other
events requiring inpatient stays.
CONCLUSION: This analysis concludes that in addition
to the favourable clinical outcome for angioplasty pa-
tients using amlodipine versus placebo demonstrated in
the CAPARES trial, a net savings in overall costs may
also be realized, resulting in dominance.
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OBJECTIVES: MEDENOX, a multinational double-
blind, placebo-controlled trial (n  1102) of venous
thromboembolism (VTE) prophylaxis among hospital-
ized, acutely ill. Medical patients revealed a lower inci-
dence of VTE among patients receiving enoxaparin 40
mg once daily for 6-14 days relative to placebo (5.5%
versus 14.9% p  .001). Conducted in Europe and Can-
ada, the trial did not include a prospective economic
component. The purpose of this study was to model the
cost-effectiveness of VTE prophylaxis with enoxaparin in
a US health-care environment from the payer perspective.
METHODS: From a national sample of US hospital sum-
mary bills, we extracted records (n  374,855) of dis-
charges matching MEDENOX diagnostic/demographic
characteristics (primary diagnoses: acute infectious dis-
ease, acute respiratory failure, or heart failure, mean age:
73 years). With these data we estimated a multivariate
model of admission cost. Regression parameters were in-
corporated in a pharmacoeconomic model of hospital ad-
mission for patients treated with or without enoxaparin
per the MEDENOX protocol. Using Monte Carlo simu-
lation, the model projected cost of admission as a func-
tion of diagnosis, length of stay, VTE prophylaxis/no
prophylaxis. Outcome measures included cost of admis-
sion, cost for VTE prophylaxis, and incremental prophy-
laxis cost per VTE avoided. Not included were potential
downstream costs for inpatient or post-hospital VTE
treatment.
RESULTS: In the base case analysis, VTE prophylaxis ac-
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counted for 1.5 percent of the average cost of admission
($125 of $7974 total cost, 90% CI: $96–$224). Relative
to no prophylaxis, the incremental cost per VTE avoided
using enoxaparin was $1330  468.
CONCLUSIONS: Acutely ill medical patients are at high
risk of VTE with treatment costs ranging from approxi-
mately $2500 (outpatient) to $25,000 (inpatient). Chronic
care for post-thrombotic syndrome, experienced in 20%-
56% of deep vein thrombosis patients further increases
the cost burden. This analysis demonstrates that VTE
prophylaxis with enoxaparin, in acutely ill medical pa-
tients has both economic and clinical benefits.
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OBJECTIVES: Cerebrovascular accidents (CVA) affect
120,000 French people each year. The aim of the study
was to calculate the cost of managing these patients.
METHODS: A Markov model was used in which four
clinical conditions were distinguished: first ischaemic
event; first cerebral haemorrhage; recurrent ischaemic
event; recurrent haemorrhagic event. Three lines of man-
agement were identified after hospitalisation: rehabilita-
tion, home, and geriatric institutions. Three levels of in-
capacity were identified using the Barthel index. Patients’
pathways in the health-care system were identified from
the only French register (Dijon) related to this disease
The specific death rates were calculated at 3, 6, 9 and 12
months. The severity of sequelae was assessed using the
Barthel index at 3 and 12 months. The clinical benefit
was measured as survival without loss of independence
(Barthel 95-100). All of the cost calculations were made
from the perspective of the community. Expenditures
were discounted at a rate of 5%.
RESULTS: The time horizon used for the model was five
years. 54.7% of the patients died during this time. The
average incapacity times after hospitalization over the
five years were: 70% slight incapacity (Barthel 95-100);
15% moderate incapacity (Barthel 60-90), and 15% se-
vere incapacity (Barthel 0-55). The total cost of manag-
ing the 120,000 cases of cerebrovascular accidents was
approximately 17 billion francs over the five years fol-
lowing the event. Twenty four percent (4.1 billion FF) of
this cost was related to short-term hospitalizations, 16.5%
(2.8 billion FF) to admissions to re-education or rehabili-
tation institutions, 33% (5.6 billion FF) to institutional
management, and 26.5% (4.5 billion FF) to looking after
patients at home. A sensitivity analysis was conducted
specially frequency with which health-care professionals
visited the patients at home.
CONCLUSION: This method allows for the calculation of
long-term costs of new cases of cerebrovascular accident.
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OBJECTIVE: The aim of the study was to assess the
costs and cost distribution of hypertension in Poland and
to compare the societal burden of hypertension on an in-
ternational basis.
METHODS: The time horizon of the analysis was 12
months and a retrospective approach was applied. The direct
medical costs of pharmacological treatment, doctor consulta-
tions, laboratory and diagnostic tests and hospitalizations
were identified and calculated. Indirect costs due to lost pro-
ductivity were also included in the analysis. All of the cost
components were collected with the aid of a cost assessment
formula, which was included in the epidemiological protocol.
RESULTS: Based on data collected from 9286 patients, the
average cost per hypertensive patient per year was calcu-
lated at 1570 PLN. The total burden of hypertension in
Poland may reach as much as 14 billion PLN per year. The
distribution of total costs is as follows: pharmacological
treatment, 10.2%; doctor consultations, 30.8%; labora-
tory and diagnostic tests, 11.4%; hospitalizations, 21.0%,
and productivity loss, 26.6%. An international compari-
son demonstrated that expenditures incurred as a result of
the pharmacological treatment of hypertension in Poland
were much lower than in other countries (i.e. Sweden:
53.3%, USA: 20.7%). Theoretically the total burden of
hypertension on society per year amounts to 31 USD in
Sweden, 82 USD in the United States and 88 USD in Po-
land using exchange rates available on January 21, 2000.
CONCLUSION: The results of the analysis demonstrate
that hypertension constitutes an important economic
burden for the Polish population. The cost of pharmaco-
logical treatment represents the lowest percentage of the
total cost of hypertension and the smallest portion of di-
rect medical costs. The conclusion is that an optimal allo-
cation of expenditure for pharmacological treatment may
contribute to a significant reduction of the total cost of
hypertension following the example of other European
countries such as Sweden as well as the United States.
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OBJECTIVE: To study costs and effectiveness of com-
mon practice treatment for critical limb ischemia at Mos-
cow hospitals.
METHODS: Data was obtained from 105 medical charts
from six Moscow hospitals. Inclusion criteria were: criti-
